受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | SCH 530348 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C29H33FN2O4 |
|||
分子量 | 492.58 | CAS No. | 618385-01-6 | |
Solubility (25°C)* | 体外 | DMSO | 99 mg/mL (200.98 mM) | |
Ethanol | 99 mg/mL (200.98 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM. |
---|---|
in vitro | SCH 530348 is a synthetic tricyclic 3-phenylpyridine and an orally active himbacine-based thrombin-receptor antagonist. SCH 530348 shows potent inhibition of thrombin-induced platelet aggregation with an IC50 of 47 nM and haTRAP-induced platelet aggregation with an IC50 of 25 nM, whereas it shows no inhibition of platelet aggregation induced by other agonists such as ADP, collagen and a PAR-4 agonist peptide. SCH 530348 also has no affect on the prothrombin time (PT), partial thromboplastin time (PTT), or activated partial thromboplastin time (aPTT). Moreover, SCH 530348 causes no increase in the bleeding time or in surgical bleeding compared with inactive control. SCH530348 is found to be selective for PAR-1 when tested over a number of ion channels and receptors, including PAR-4 receptor. [1] |
in vivo | SCH 530348 is well absorbed in rat (68%; 10 mg/kg) and in monkey (82%; 1 mg/kg) models. Tmax is observed at about 3 h in rats and 1 h in monkeys. The elimination half-life is 5.1 h in rats and 13 h in monkeys. The oral bioavailability is 33% in rats and 86% in monkeys. In preclinical studies in cynomolgus monkey platelets, oral administration of SCH 530348 at a dose greater than 0.1 mg/kg resulted in 100% inhibition of thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation for 24 h with partial recovery occurring at 48 h. [1] |
キナーゼアッセイ | In vitro PAR-1 binding assay | |
---|---|---|
Human platelet membranes (700 mg) are prepared from 40 units of fresh human platelets. Thrombin receptor antagonists are screened using a modification of the thrombin receptor radioligand binding assay Human platelet membranes (40μg) are incubated with 10nM of [3H]haTRAP (alanine-p-fluorophenylalaninearganine-cyclohexylalanine-homoarganine-[ 3H]phenylalanine amide) in the presence of compounds at concentrations of 1 nM, 3 nM, 30 nM, 100 nM, 300 nM and 1μM (5% DMSO final concentration) in binding buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.1% BSA). The plates are covered and vortex-mixed gently on a plate shaker for 1 h at room temperature. The incubated membranes are harvested using a Packard FilterMate Universal Harvester onto Packard UniFilter GF/C filter plates which are soaked for at least 1 hour in 0.1% polyethyleneimine and then rapidlywashed four times with 300 μL ice cold binding buffer without BSA. MicroScint 20 scintillation cocktail is added to each well, and the plates are counted in a Packard TopCount Microplate Scintillation Counter. The specific binding is defined as the total binding minus the nonspecific binding observed in the presence of excess (50 μM) unlabeled haTRAP. | ||
細胞アッセイ | 細胞株 | HCASMC cells |
濃度 | 8.1 nM | |
反応時間 | ||
実験の流れ | Cells were treated with different concentrations of SCH 530348. |
|
動物実験 | 動物モデル | cynomolgus monkeys |
投薬量 | 0.5, 0.3, 0.1, and 0.05 mg/kg | |
投与方法 | oral |
Rivaroxaban attenuates neutrophil maturation in the bone marrow niche [ Basic Res Cardiol, 2023, 118(1):31] | PubMed: 37580509 |
The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies [ Nutrients, 2023, 15(8)1842] | PubMed: 37111061 |
The Antiplatelet Effect of 4-Methylcatechol in a Real Population Sample and Determination of the Mechanism of Action [ Nutrients, 2022, 14(22)4798] | PubMed: 36432485 |
Comparison of Antiplatelet Effects of Phenol Derivatives in Humans [ Biomolecules, 2022, 12(1)117] | PubMed: 35053265 |
Probing the signaling requirements for naive human pluripotency by high-throughput chemical screening [ Cell Rep, 2021, 35(11):109233] | PubMed: 34133938 |
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer [ EMBO Mol Med, 2020, 12(8):e11987] | PubMed: 32672423 |
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer [ EMBO Mol Med, 2020, 12(8):e11987] | PubMed: 32672423 |
Dabigatran Suppresses PAR-1/SphK/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model [ Front Mol Neurosci, 2020, 13:114] | PubMed: 32694981 |
Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury. [ J Surg Res, 2020, 246:568-583] | PubMed: 31653415 |
The Establishment and Validation of the Human U937 Cell Line as a Cellular Model to Screen Immunomodulatory Agents Regulating Cytokine Release Induced by Influenza Virus Infection [ Virol Sin, 2019, 34(6):648-661] | PubMed: 31286365 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。